Jon Gelman has been named again to Best Lawyers in America®. This recognition has been bestowed upon him for well over a decade.

Selection to Best Lawyers® is based on an exhaustive and rigorous peer-review survey comprising more than 2.5 million confidential evaluations by the top attorneys in the country. Because no fee or purchase is required, being listed in Best Lawyers is considered a singular honor. Our annual, advertisement-free publication has been described in The American Lawyer as “the most respected referral list of attorneys in practice.”
 

Jon L Gelman is investigating cases involving individuals who have suffered a heart attack, ischemic stroke or other cardiac condition while taking Avandia for diabetes.

Jon Gelman is investigating cases involving infant drugs manufactured by pharmaceutical company McNeil Consumer Healthcare including include certain liquid infant’s and children’s Tylenol®, Motrin®, Zyrtec®, and Benadryl® products.

Jon Gelman is investigating cases involving Paxil users who have a child who suffered birth malformations after being exposed to Paxil within any trimester of pregnancy. Paxil and Paxil CR® are antidepressants manufactured by the pharmaceutical company GlaxoSmithKline.

Jon L. Gelman has been named to the 2010 edition of New Jersey Super Lawyers. Each year, only 5 percent of the lawyers in the state receive this honor.

 FDA requires manufacturer of Botox® to post warning on its product of potential adverse reactions.

On July 10, 2009, Medtronic, Inc., announced a defect in the Paradigm® Quick-Set® Infusion Sets. The company identified a potentially high rate of failure of the system to function properly and deliver medication to the patient in an accurate manner through the pump.

Jon L. Gelman is accepting cases in which recipients of transvaginal mesh/sling products have suffered from complications. Transvaginal meshes are implanted through surgery. According to the FDA, contributing factors to complications potentially include the patient’s health, mesh material, the size and shape of the mesh, surgical procedures and estrogen levels.

In July 2008, the FDA announced a mandatory black box warning label for fluoroquinolone drugs that highlights and strengthens the warning for increased risk of tendonitis and tendon rupture

Jon L. Gelman LLC is investigating cases involving individuals who have suffered the loss of taste and smell (anosmia) after using Zicam®. Zicam® is an over-the-counter nasal spray used to relieve the symptoms associated with the common cold and flu and is manufactured by Matrixx Initiatives. Matrixx manufactures a range of products under the Zicam® name, but the name Zicam® is generally used to refer to its over-the-counter nasal zinc solution spray.  

We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.

On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
 

The US Centers for Disease Control (CDC) has issued an alert for the spread of human swine flu virus. Employers and employees will now need to be alerted to preparations and the reactions that may occur.

Jon L. Gelman  is investigating potential cases involving users of Hydroxycut® products who have experienced health problems that may include Rha...

On January 1, 2009 we relocated to newer and more modern office space.

 The U.S. Consumer Product Safety Commission, in cooperation with the firm named below, today announced a voluntary recall of "Bagi Shumanit" Super Cold Grease Removers. Consumers should stop using recalled products immediately unless otherwise instructed.

The U.S. Consumer Product Safety Commission (CPSC), in cooperation with Delta Enterprise Corp., of New York, New York., announced the recall to replace missing safety pegs involving 985,000 drop side cribs. Failure to use or install safety pegs can cause an entrapment and suffocation risk to infants and toddlers.
 

Fosamax® (alendronate sodium tablets and oral solution) is a bisphosphonate manufactured by Merck, that is marketed, advertised, distributed and sold for the treatment of osteoporosis and Paget’s Disease. It has additionally been prescribed for off label uses such as bone cancers. Fosamax® tablets were approved by the FDA on September 29, 1995, while the oral solution was approved on September 17, 2003.

NuvaRing® is a vaginal ring contraceptive medication that was approved by the FDA in October 2001. The drug is manufactured by Organon USA, Inc., based in New Jersey, which was acquired by Schering-Plough Corporation in 2007. Since its initial FDA approval and use on the market, NuvaRing® has been linked to serious venous thromboembolic events including blood clots, pulmonary embolism, stroke and myocardial infarction, or heart attack.
 

PROVIGIL is a medication that has the active ingredient of Modanifil and is used to treat excessive sleepiness caused by certain sleep disorders. These sleep disorders are narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In addition to its wakefulness-promoting effects, PROVIGIL produces psychoactive and euphoric effects, alterations in mood, perception, thinking, and feelings typical of other central nervous system stimulants.

On October 14, 2007, Medtronic, the nation's largest heart implant device manufacturer, announced a defect in the critical electrical "lead" component of its heart defibrillator. The New York Times reported on October 15, 2007, that the defect in this electrical wire, called the Sprint Fidelis, has resulted in hundreds of malfunctions and may have